EyePoint Pharmaceuticals Welcomes New CMO Dr. Ramiro Ribeiro, Eyes Phase 3 Trials

WATERTOWN, Mass., March 04, 2024 – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pioneering firm in retinal disease therapeutics, has announced Dr. Ramiro Ribeiro, M.D., Ph.D., as its new Chief Medical Officer (CMO), taking over from Dr. Dario Paggiarino. Dr. Ribeiro's appointment comes at a pivotal moment for EyePoint, with significant clinical trials on the horizon.

Leadership Transition and Strategic Vision

"We are delighted to welcome Dr. Ribeiro to the EyePoint senior leadership team during an exciting time as we approach the anticipated Phase 2 PAVIA trial readout of EYP-1901 for NPDR in the second quarter and the initiation of our first Phase 3 LUGANO pivotal trial in wet AMD in the second half of this year," expressed Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals. Dr. Ribeiro, with a robust background in clinical development from his tenure at Apellis Pharmaceuticals, is poised to leverage his expertise in advancing EyePoint's mission of bringing novel retinal disease therapies to market. The company also extends its gratitude to Dr. Paggiarino for his invaluable contributions over the years.

Innovative Therapeutic Development

Dr. Ribeiro is set to play a crucial role in the progression of EyePoint's flagship product, EYP-1901, through critical Phase 3 trials. “I have devoted my career to bringing innovative treatments to patients suffering from sight-threatening conditions, and I believe that intravitreal sustained-delivery therapies using EyePoint's Durasert E technology have great potential to transform the treatment paradigm for serious retinal diseases," said Dr. Ribeiro. His enthusiasm for pioneering treatments aligns with EyePoint's strategic vision as the company aims to solidify its leadership in sustained intraocular drug delivery.

Looking Ahead: Clinical Trials and Patient Impact

As EyePoint gears up for the Phase 3 LUGANO pivotal trial in wet AMD and anticipates the Phase 2 PAVIA trial readout, the appointment of Dr. Ribeiro marks a significant milestone. The compelling efficacy and safety data observed in the Phase 1 DAVIO and Phase 2 DAVIO 2 trials underscore the potential of EYP-1901. Dr. Ribeiro's leadership is expected to catalyze the development of EyePoint's portfolio, promising novel treatment options for patients worldwide. Under Dr. Ribeiro's guidance, EyePoint is poised to navigate the next chapters of clinical development and regulatory approval, aiming to transform the treatment landscape for serious retinal diseases.